Advanced search
Publication Cover
Patient Preference and Adherence Volume 17, 2023 - Issue
Submit an article Journal homepage
186
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Real-World Experience of People with Hemophilia A Receiving Turoctocog Alfa Pegol (N8-GP): Results from a Patient Experience Survey

Hermann Eichler1 Institute of Clinical Hemostaseology and Transfusion Medicine, Saarland University, Homburg, GermanyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1372-0619
ORCID Icon,
Azusa Nagao2 Department of Blood Coagulation, Ogikubo Hospital, Tokyo, Japan
,
John Waller3 Novo Nordisk, Zurich, Switzerland
&
Alexander Stuber4 Patient Author, Braunwald, Switzerland
Pages 3001-3014 | Received 26 Jul 2023, Accepted 08 Nov 2023, Published online: 16 Nov 2023

References

  • Gringeri A, Ewenstein B, Reininger A. The burden of bleeding in haemophilia: is one bleed too many? Haemophilia. 2014;20(4):459–463. doi:10.1111/hae.12375
  • Okaygoun D, Oliveira DD, Soman S, Williams R. Advances in the management of haemophilia: emerging treatments and their mechanisms. J Biomed Sci. 2021;28(1):64. doi:10.1186/s12929-021-00760-4
  • Mannucci PM. Hemophilia therapy: the future has begun. Haematologica. 2020;105(3):545–553. doi:10.3324/haematol.2019.232132
  • Srivastava A, Santagostino E, Dougall A, et al. WFH guidelines for the management of hemophilia. Haemophilia. 2020;26(Suppl 6):1–158. doi:10.1111/hae.14046
  • Chowdary P. Extended half-life recombinant products in haemophilia clinical practice - expectations, opportunities and challenges. Thromb Res. 2020;196:609–617. doi:10.1016/j.thromres.2019.12.012
  • McCall M, Koerner P, Miller R, Radi M. Comparison of extended to standard half-life recombinant factor VIII therapy in patients with hemophilia A on prophylactic therapy. J Drug Assess. 2019;8(sup1):46–47. doi:10.1080/21556660.2019.1658327
  • Tiede A. Half-life extended factor VIII for the treatment of hemophilia A. J Thromb Haemost. 2015;13(Suppl 1):S176–S179. doi:10.1111/jth.12929
  • Stennicke HR, Kjalke M, Karpf DM, et al. A novel B-domain O-glycoPEGylated FVIII (N8-GP) demonstrates full efficacy and prolonged effect in hemophilic mice models. Blood. 2013;121(11):2108–2116. doi:10.1182/blood-2012-01-407494
  • Lentz SR, Kavakli K, Klamroth R, et al. Turoctocog alfa pegol (N8-GP) in severe hemophilia A: long-term safety and efficacy in previously treated patients of all ages in the pathfinder8 study. Res Pract Thromb Haemost. 2022;6(2):e12674. doi:10.1002/rth2.12674
  • Chodankar D. Introduction to real-world evidence studies. Perspect Clin Res. 2021;12(3):171–174. doi:10.4103/picr.picr_62_21
  • Baumfeld Andre E, Reynolds R, Caubel P, Azoulay L, Dreyer NA. Trial designs using real-world data: the changing landscape of the regulatory approval process. Pharmacoepidemiol Drug Saf. 2020;29(10):1201–1212. doi:10.1002/pds.4932
  • Wong ELY, Xu RH, Cheung AWL. Health-related quality of life among patients with hypertension: population-based survey using EQ-5D-5L in Hong Kong SAR, China. BMJ Open. 2019;9(9):e032544. doi:10.1136/bmjopen-2019-032544
  • Kearney S, Raffini LJ, Pham TP, et al. Health-related quality-of-life and treatment satisfaction of individuals with hemophilia A treated with turoctocog alfa pegol (N8-GP): a new recombinant extended half-life FVIII. Patient Prefer Adherence. 2019;13:497–513. doi:10.2147/PPA.S196103
  • Giangrande P, Andreeva T, Chowdary P, et al. Clinical evaluation of glycoPEGylated recombinant FVIII: efficacy and safety in severe haemophilia A. Thromb Haemost. 2017;117(2):252–261. doi:10.1160/TH16-06-0444
  • Waldman LT, Busk AK, Lee XY, Brod M. Exploring the treatment experiences of adolescent and adult patients with haemophilia A: exit interview findings from the pathfinder 8 trial (PO059). Haemophilia. 2022;28(S1):25–126. Presented at Annual Congress of European Association for Haemophilia and Allied Disorders.
  • Klamroth R, Hampton K, Saulyte Trakymienė S, Korsholm L, Carcao M. Illustrative cases from the pathfinder clinical trials of patients with hemophilia A treated with turoctocog alfa pegol (N8-GP). Patient Prefer Adherence. 2021;15:2443–2454. doi:10.2147/PPA.S326282
  • Forsyth AL, Witkop M, Lambing A, et al. Associations of quality of life, pain, and self-reported arthritis with age, employment, bleed rate, and utilization of hemophilia treatment center and health care provider services: results in adults with hemophilia in the HERO study. Patient Prefer Adherence. 2015;9:1549–1560. doi:10.2147/PPA.S87659
  • Banchev A, Batorova A, Faganel Kotnik B, et al. A cross-national survey of people living with hemophilia: impact on daily living and patient education in Central Europe. Patient Prefer Adherence. 2021;15:871–883. doi:10.2147/PPA.S303822
  • O’Hara S, Castro FA, Black J, et al. Disease burden and remaining unmet need in patients with haemophilia A treated with primary prophylaxis. Haemophilia. 2021;27(1):113–119. doi:10.1111/hae.14171

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.